The complement system is a major, multifunctional part of innate immunity and serves as a bridge between the innate and adaptive immune systems. It consists of more than 30 distinct proteins that interact with one another in a specific sequence. There are three pathways of complement activation: the classical, the lectin, and the alternative pathways. The three pathways are initiated by distinct mechanisms, but they all generate the same core set of effector molecules. Inherited complete deficiencies in complement components are generally very rare and predispose to infections and autoimmune disease. One of the better described associations is between deficiencies in early classical pathway components and the development of systemic lupus erythematosus. The goal of this review will be to discuss the associations between and the causal mechanisms of complement deficiencies and systemic lupus erythematosus.
This is a preview of subscription content, log in to check access.
Compliance with Ethics Guidelines
Conflict of Interest
Angela Bryan and Eveline Wu declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Frank MM. Complement disorders and hereditary angioedema. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S262–71. This paper provides a more detailed review of the complement activation pathways and their regulators as well as a brief discussion of deficiencies in the complement system.PubMedCrossRefGoogle Scholar
Ballanti E et al. Complement and autoimmunity. Immunol Res. 2013;56(2–3):477–91. This paper provides recent, thorough discussion of the complement system and its role in the pathogenesis of a spectrum of autoimmune diseases.PubMedCrossRefGoogle Scholar
Chen M, Daha MR, Kallenberg CG. The complement system in systemic autoimmune disease. J Autoimmun. 2010;34(3):J276–86.PubMedCrossRefGoogle Scholar
Pettigrew HD, Teuber SS, Gershwin ME. Clinical significance of complement deficiencies. Ann N Y Acad Sci. 2009;1173:108–23. This paper provides a more comprehensive overview of the diversity of clinical manifestations of deficiencies in the complement system.PubMedCrossRefGoogle Scholar
Lewis MJ, Botto M. Complement deficiencies in humans and animals: links to autoimmunity. Autoimmunity. 2006;39(5):367–78.PubMedCrossRefGoogle Scholar
Inai S et al. Inherited deficiencies of the late-acting complement components other than C9 found among healthy blood donors. Int Arch Allergy Appl Immunol. 1989;90(3):274–9.PubMedCrossRefGoogle Scholar
Deapen D et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992;35(3):311–8.PubMedCrossRefGoogle Scholar
Sturfelt G, Truedsson L. Complement and its breakdown products in SLE. Rheumatology (Oxford). 2005;44(10):1227–32.CrossRefGoogle Scholar
Sontheimer RD, Racila E, Racila DM. C1q: its functions within the innate and adaptive immune responses and its role in lupus autoimmunity. J Invest Dermatol. 2005;125(1):14–23.PubMedCrossRefGoogle Scholar
Gullstrand B et al. Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol. 2009;156(2):303–11.PubMedCentralPubMedCrossRefGoogle Scholar
Lood C et al. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum. 2009;60(10):3081–90.PubMedCrossRefGoogle Scholar
Fraser DA et al. C1q and MBL, components of the innate immune system, influence monocyte cytokine expression. J Leukoc Biol. 2006;80(1):107–16.PubMedCrossRefGoogle Scholar
Botto M et al. Complement in human diseases: lessons from complement deficiencies. Mol Immunol. 2009;46(14):2774–83.PubMedCrossRefGoogle Scholar
Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol. 2004;22:431–56.PubMedCrossRefGoogle Scholar
Vassallo G et al. Clinical variability and characteristic autoantibody profile in primary C1q complement deficiency. Rheumatology (Oxford). 2007;46(10):1612–4.CrossRefGoogle Scholar
Boteva L et al. Genetically determined partial complement C4 deficiency states are not independent risk factors for SLE in UK and Spanish populations. Am J Hum Genet. 2012;90(3):445–56.PubMedCentralPubMedCrossRefGoogle Scholar
Jonsson G et al. Rheumatological manifestations, organ damage and autoimmunity in hereditary C2 deficiency. Rheumatology (Oxford). 2007;46(7):1133–9.CrossRefGoogle Scholar
Palarasah Y et al. Novel assays to assess the functional capacity of the classical, the alternative and the lectin pathways of the complement system. Clin Exp Immunol. 2011;164(3):388–95.PubMedCentralPubMedCrossRefGoogle Scholar
Ohlenschlaeger T et al. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med. 2004;351(3):260–7.PubMedCrossRefGoogle Scholar
Steinsson K, Erlendsson K, Valdimarsson H. Successful plasma infusion treatment of a patient with C2 deficiency and systemic lupus erythematosus: clinical experience over forty-five months. Arthritis Rheum. 1989;32(7):906–13.PubMedGoogle Scholar
Erlendsson K et al. Reciprocal changes in complement activity and immune-complex levels during plasma infusion in a C2-deficient SLE patient. Lupus. 1993;2(3):161–5.PubMedCrossRefGoogle Scholar
Hudson-Peacock MJ et al. Systemic lupus erythematosus complicating complement type 2 deficiency: successful treatment with fresh frozen plasma. Br J Dermatol. 1997;136(3):388–92.PubMedCrossRefGoogle Scholar
Mehta P et al. SLE with C1q deficiency treated with fresh frozen plasma: a 10-year experience. Rheumatology (Oxford). 2010;49(4):823–4.CrossRefGoogle Scholar
Martini PG et al. Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases. BMC Immunol. 2010;11:43. This paper provides proof of concept that recombinant complement proteins may be successfully produced and may restore functional activity in the setting of complement deficiency.PubMedCentralPubMedCrossRefGoogle Scholar